Biosergen publishes interim report for second quarter 2022
Wednesday, August 31, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q2 2022
| 2022 | 2021 | 2022 | 2021 | 2021 | |
| TSEK | April-June | April-June | Jan-June | Jan-June | Jan-Dec |
| Consolidated group revenue | 1.409 | 2.001 | 2.726 | 2.001 | 11.570 |
| Consolidated group loss before depreciation | -7.963 | -9.493 | -12.981 | -17.798 | -34.077 |
| Consolidated group loss befor net financials | -7.963 | -9.493 | -12.981 | -8.305 | -34.077 |
| Consolidated net result | -7.960 | -9.504 | -12.975 | -17.809 | -34.318 |
| Consolidated earnings per share (EPS) | -0,28 | -0,59 | -0,46 | -1,10 | -1,22 |
Highlights during Q2 2022
- April 7, The first subject has been dosed in the phase 1 trial og BSG005
- May 13, Biosergen successfully completes first cohort of BSG005 phase 1 trial
- June 30, Biosergen successfully completes second cohort of BSG005 phase 1 trial
Highlights after the period
- August 26, Biosergen completes the third cohort of BSG005 phase 1 trial
- August 31, Biosergen receives a loan of SEK 7 million to finance continued development
The Financial report can be found on our website: https://biosergen.net/investors/filings
